Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, November 29, 2014
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

New LEGENDplex™ Multi-Analyte Flow Assay Panels for Simultaneous Quantification of 13 Th Cytokines in Human and Mouse Samples
Binggang Sun, Jingjing Yao, Jiaming Hu and Shaoquan Ji

We have developed two multiplexed assay panels, human and mouse, using fluorescence–encoded beads, suitable for use on various flow cytometers. Both panels allow simultaneous quantification of 13 human or mouse cytokines, including interleukins (IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 21, 22), IFN-? and TNF-a. These Th cytokine panels can be used for serum, plasma, cell culture supernatant and other sample types, offering useful tools for biomedical research and drug discovery.

More information
Multi-Color Fluorescence Microscopy Application using Novel Brilliant Violet™ and Alexa Fluor® 594 Conjugated Monoclonal Antibodies
Hong Zhang, Kelly Lundsten, Kevin Williams, Beibei Ding, Xiao Lin, Xifeng Wang, Jie Zhou, Dzung Nguyen, and John Ransom

Development of valuable new tools for the immunologist, to resolve multiple antigens simultaneously with fluorescence microscopy: Brilliant Violet 421™, Alexa Fluor® 488, Alexa Fluor® 594 and Alexa Fluor® 647 conjugated monoclonal antibodies.

More information
Discrimination of spectrally overlapping fluorochromes using Sony Corporation’s (SP6800) Spectral Analyzer
Divekar AA, Lee MJ, Kakuta M, Nitta N, Furuki M, Yang XF and Ransom JT

SP6800, a novel spectral analyzer from Sony Corporation, uses an innovative optics system that collects all emitted light and eliminates the need for band pass filters. Our data show that the SP6800 can perform all the analysis similar to a traditional cytometer with the added feature of separating spectrally overlapping fluorophores.

More information
Comparison of Three Methods for the Evaluation of Cytokine Storm Risk in Early and Clinical Stage Biopharmaceutical Development
Gary dos Santos and Emer Clarke

Objective: To identify an assay that can accurately predict the risk of CRS and CS associated with investigational biotherapeutics. A comparison of three methods were used: (a) immobilization of test antibody on plastic, (b) co-culture of PBMC's on HUVEC's and (c) pre-culture of PBMC's at high cell density.

More information
Stealth-Adapted Viruses and Viteria: Insights into Virus Construction, Replication and Potential Therapies
W. John Martin

There is an increasing incidence of diseases with accompanying signs and symptoms of brain damage. These include neurological and psychiatric illnesses, childhood behavioral disorders, and such common conditions as chronic fatigue, Gulf War Syndrome, so-called “chronic Lyme disease”, and many cancers. Altogether, these diseases have an enormous social impact.

More information
Hypothesis of an Existence of a Reverse Pathway (Rp) which Passes Genetic Information from Polypeptide Antigens to Ig Genes in B-Lymphocytes
Victor J. Alexander

Results of this research will bring new more effective treatment methods of many immune related diseases, including cancer.

More information
A mix-and-read cell-based assay for antibody screening against Epithelial Growth Factor Receptor
Wayne P Bowen, David Onley, Paul Wylie, Diana Caracino and Tristan Cope

Here we present a sensitive robust, mix-and-read method for the screening of antibodies against cell surface proteins. With its simple operation, no-wash format, and high sensitivity, this new method is well-suited for high throughput antibody screening.

More information
Random Homozygous Gene Perturbation (RHGP) as a Tool for Target Discovery and Validation
Wu-Bo Li and Michael Goldblatt

Random homozygous gene perturbation (RHGP) can identify and validate any host (cellular) gene target that directly causes a desired phenotype without requiring prior knowledge of the target. The central feature of RHGP is a unique lentiviral-based genetic element, known as a gene search vector (GSV) designed to interrogate the entire genome and identify target genes that cause the phenotype of interest.

More information
Metal Polymers, A Glue to Immobilise Proteins Onto Synthetic Surfaces
Abernethy N, Chung E, Fontanelle BT, Gao Y, Jennins D, Koudijs MM, Lim D, Yang L, Ling T, Vukovic P, Wong A, Maeji, NJ

The main objective of this work was to develop a surface chemistry which maintains protein function and orientation per unit surface area, regardless of the surface used.

More information
<< 1 2 3 >>
Showing Results 11 - 20 of 29
Scientific News
Protein Predicts Response To New Immunotherapy Drug
Trial shows that response to treatment may be predicted by the presence of an immune-suppressing protein in non-cancerous immune cells.
A Hybrid Vehicle That Delivers DNA
University at Buffalo researchers are developing new technology to improve DNA vaccines. The new transport system for DNA vaccines could help treat HIV, malaria, HPV and other major illnesses.
New Study Reveals Why Some People May be Immune to HIV-1
Natural genetic variation in a protective antiviral enzyme holds promise for new therapies.
Bacterial Toxin Targets Discovered
Understanding how bacterial toxins target human cells is set to have major implications for the development of novel drugs.
Monitoring Effectiveness Of Hay Fever Immunotherapy
A new test for measuring histamine release from certain white blood cells could help doctors monitor the effectiveness of immunotherapy for hay fever.
Precisely Off The Mark
Possible cause discovered for failure of targeted liver cancer therapies.
Drugs to Block Angiogenesis Could Provide New Treatment for TB
Blood supply gives invaders oxygen and a way out.
Researchers Tease Out Glitches in Immune System's Self-Recognition
A new study revises understanding of how the process works and sheds light on autoimmune disease.
Breakthrough in Managing Yellow Fever Disease
UC Riverside-led research could lead to antiviral therapeutics and better diagnostics to prevent spread of potentially fatal viral infection.
Anti-Leukemia Drug May Also Work Against Ovarian Cancer
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well.
Skyscraper Banner
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv